Shenzhen Kangtai Biological Products Co Ltd Market Cap ($2.08 Billion)
Market Cap & Net Worth: Shenzhen Kangtai Biological Products Co Ltd (300601)
Shenzhen Kangtai Biological Products Co Ltd market cap. Shenzhen Kangtai Biological Products Co Ltd (SHE:300601) has a market capitalization of $2.08 Billion (CN¥14.19 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #5851 globally and #1063 in its home market, demonstrating a 0.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Kangtai Biological Products Co Ltd's stock price CN¥12.70 by its total outstanding shares 1116930267 (1.12 Billion). Also see 300601 operating cash flow for how efficiently the company converts equity into cash flow.
Shenzhen Kangtai Biological Products Co Ltd Market Cap History (2017–2026)
Shenzhen Kangtai Biological Products Co Ltd market cap history from 2017 to 2026. Data shows growth from $3.07 Billion to $2.08 Billion (21.67% CAGR). Check Shenzhen Kangtai Biological Products Co share price for real-time trading data and today's change.
Index Memberships
Shenzhen Kangtai Biological Products Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$932.54 Billion | 0.22% | #81 of 100 |
Weight: Shenzhen Kangtai Biological Products Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Shenzhen Kangtai Biological Products Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Kangtai Biological Products Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Shenzhen Kangtai Biological Products Co (300601) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.90x
Shenzhen Kangtai Biological Products Co Ltd's market cap is 0.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
34.32x
Shenzhen Kangtai Biological Products Co Ltd's market cap is 34.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $3.07 Billion | $1.16 Billion | $214.70 Million | 2.64x | 14.28x |
| 2018 | $3.48 Billion | $2.02 Billion | $435.69 Million | 1.73x | 7.99x |
| 2019 | $8.58 Billion | $1.94 Billion | $574.51 Million | 4.42x | 14.94x |
| 2020 | $17.08 Billion | $2.26 Billion | $679.19 Million | 7.55x | 25.15x |
| 2021 | $9.67 Billion | $3.65 Billion | $1.26 Billion | 2.65x | 7.66x |
| 2022 | $5.06 Billion | $3.16 Billion | -$132.71 Million | 1.60x | N/A |
| 2023 | $4.39 Billion | $3.48 Billion | $861.30 Million | 1.26x | 5.09x |
| 2024 | $2.80 Billion | $2.65 Billion | $201.65 Million | 1.06x | 13.90x |
| 2025 | $2.41 Billion | $2.67 Billion | $70.33 Million | 0.90x | 34.32x |
Competitor Companies of 300601 by Market Capitalization
Companies near Shenzhen Kangtai Biological Products Co Ltd in the global market cap rankings as of November 5, 2026. Also see 300601 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Shenzhen Kangtai Biological Products Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Shenzhen Kangtai Biological Products Co Ltd (2017–2026)
Market capitalization of Shenzhen Kangtai Biological Products Co Ltd from 2017 to today. Between 2017 and today, Shenzhen Kangtai Biological Products Co Ltd's market cap moved from $3.07 Billion to $ 2.08 Billion, with a yearly change of 21.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.08 Billion | -14.01% |
| 2025 | CN¥2.41 Billion | -13.88% |
| 2024 | CN¥2.80 Billion | -36.09% |
| 2023 | CN¥4.39 Billion | -13.37% |
| 2022 | CN¥5.06 Billion | -47.65% |
| 2021 | CN¥9.67 Billion | -43.37% |
| 2020 | CN¥17.08 Billion | +99.07% |
| 2019 | CN¥8.58 Billion | +146.43% |
| 2018 | CN¥3.48 Billion | +13.54% |
| 2017 | CN¥3.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Shenzhen Kangtai Biological Products Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.08 Billion USD |
| MoneyControl | $2.08 Billion USD |
| MarketWatch | $2.08 Billion USD |
| marketcap.company | $2.08 Billion USD |
| Reuters | $2.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus ace… Read more